All News

2017

September

Media Release / Sep 12, 2017

Sandoz proposed biosimilar rituximab accepted for review by the FDA

Read More

August

Media Release / Aug 29, 2017

Sandoz invests in major expansion of global headquarters in Holzkirchen, Germany

Read More
Media Release / Aug 29, 2017

Lancet Haematology publishes data demonstrating Sandoz Rixathon® (biosimilar rituximab) matches efficacy and safety of reference biologic

Read More

July

Media Release / Jul 25, 2017

Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries

Read More
Media Release / Jul 18, 2017

Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products

Read More

June

Media Release / Jun 27, 2017

Sandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseases

Read More
Media Release / Jun 19, 2017

Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

Read More
Media Release / Jun 15, 2017

FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®

Read More
Media Release / Jun 13, 2017

US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines

Read More
Media Release / Jun 12, 2017

US Supreme Court clears way to early access to biosimilars

Read More

Pages